Axatilimab Trial
Phase 1/2
38
about 4.9 years
18+
1 site in OR
What this study is about
This trial is testing the safety, side effects, and effectiveness of axatilimab when combined with retifanlimab and paclitaxel for people with advanced or metastatic solid tumors. Axatilimab is a monoclonal antibody that may interfere with tumor growth and spread. Retifanlimab helps the immune system attack cancer cells, and paclitaxel stops cancer cell growth and division. This combination treatment aims to be safe, tolerable, and potentially effective in treating these cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Axatilimab
- 2.Receive Retifanlimab
- 3.Take Paclitaxel
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Anti-inflammatory Agent (Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors), paclitaxel (Taxane chemotherapy; stabilizes microtubules), retifanlimab
injection, intravenous
biopsy, diagnostic, imaging
Oncology